Athanasios Karampeazis, Alexandra Voutsina, John Souglakos, Nikos Kentepozidis, Stelios Giassas, Charalambos Christofillakis, Athanasios Kotsakis, Pavlos Papakotoulas, Ageliki Rapti, Maria Agelidou, Sofia Agelaki, Lambros Vamvakas, George Samonis, Dimitris Mavroudis and Vassilis Georgoulias Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study Cancer 119
Article first published online: 9 MAY 2013 | DOI: 10.1002/cncr.28132
Both pemetrexed and erlotinib are active in patients with pretreated non–small cell lung cancer (NSCLC). In this randomized controlled phase 3 trial, the 2 drugs are compared, and the results indicate that both agents are equally effective in unselected patients with previously treated NSCLC, although they have different toxicity profiles. Exploratory biomarker analyses indicate no difference in efficacy irrespective of EGFR status, whereas the presence of KRAS mutations is correlated with treatment efficacy.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.